Abstract

  In the past structural diversity of natural products have inspired mainly organic and medicinal chemists, looking for new pharmacophoric fragments useful for design of novel drugs. Ethnopharmacology and its more recent advanced form – pharmacognosy, classified plants into poisonous and curative categories, but practically neglected chemical components of plants cultivated for food and feed. Contemporary life sciences drawing from newly acquired knowledge of genomics, genetic engineering, and systems biology, have largely changed traditional landscape of strictly divided disciplines and fields of science. Fading borders between natural product chemistry, pharmacology, biochemistry and nutrition sciences, call for a new look at renewable biological resources and designing most rational way of their exploitation. In particular, beside cultivated medicinal plants, from which active pharmaceuticals are isolated with due care, other kinds of biomass including agricultural crops, spices, vegetables and fruits, should be looked at as multipurpose raw materials, which contain some valuable phytochemicals, compounds of considerable potential for improving human health and well-being.

Keywords: Natural Products; Plant Metabolites; Plant Phenolics; Flavonoids; Health Benefits; Chemoprevention

References

1. Duke JA., “Handbook of Biologically Active Phytochemicals and Their Activities”. CRC Press, Boca Raton, FL, USA (1992).
2. Crozier A., et al. “Plant Secondary Metabolites Occurrence, Structure and Role in the Human Diet”. Blackwell Publishing LTD. London (2006).
3. Rao V. “Phytochemicals – a global perspective of their role in nutrition and health” Intechopen.com Rijeka CR (2012).
4. Huang L. “Molecular Pharmacognosy”. Springer, Dordrecht (2013).
5. Newman DJ., et al. “The influence of natural products upon drug discovery”. Natural Product Reports 17 (2000): 215-234.
6. Newman DJ and Cragg GM. “Natural Products as Sources of New Drugs from 1981 to 2014”. Journal of Natural Products3 (2016): 629-661.
7. Kaneko K. “Life: an introduction to complex systems biology”. Springer-Verlag, Berlin (2006).
8. Klipp E., et al. Systems biology: a textbook, 2nd Edition, Wiley-VCH Weinheim (2016).
9. Sporn M.B., et al. “Prevention of chemical cancerogenesis by vitamin A and its synthetic analogs”. Federation Proceedings6 (1976): 1332-1338.
10. Sporn MB and Liby KT. “Cancer chemoprevention: scientific promise, clinical uncertainty”. Nature Clinical Practice Oncology10 (2005): 518-528.
11. Greiner AK., et al. “Chemoprevention in gastrointestinal physiology and disease. Natural products and microbiome”. American Journal of Physiology Gastrointestinal Liver Physiology1 (2014): G1-G15.
12. Madrigal-Santillan E., et al., “The chemoprevention of chronic degenerative disease through dietary antioxidants: progress, promise and evidences”. in: Oxidative Stress and Chronic Degenerative Diseases - A Role for Antioxidants, Intech Open Rijeka (2013): 155-185.
13. Ramawat KG and Mérillon JM. “Bioactive Molecules and Medicinal Plants”. Springer Verlag Berlin (2008).
14. Prakash D and Sharma G. “Phytochemicals of nutraceutical importance”. CAB International Boston MA USA (2014).
15. DeFelice SL., “The nutraceutical revolution: its impact on food industry R&D”. Trends in Food Science and Technology 6 (1995): 59-61.
16. Dillard CJ and German JB., “Phytochemicals: nutraceuticals and human health”. Journal of the Science of Food and Agriculture 80 (2000): 1844-1856.
17. Zeisel SH., “Regulation of nutraceuticals". Science 285 (1999): 185-186.
18. Augustin MA and Sanguansri L. “Challenges and solutions to incorporation of nutraceuticals in foods”. Annual Review of Food Science and Technology 6 (2015): 463–477.
19. Schmitt J and Ferro A. “Nutraceuticals: is there good science behind the hype?”. British Journal of Clinical Pharmacology 75 (2013): 585–587.
20. Aronson JK., “Defining ‘nutraceuticals’: neither nutritious nor pharmaceutical”. British Journal of Clinical Pharmacology 83 (2017): 8–19.
21. Estruch R., et al. “Primary prevention of cardiovascular disease with a Mediterranean diet”. New England Journal of Medicine 368 (2013): 1279–1290.
22. Williams RJ., et al. “Neuro-nutraceuticals: The path to brain health via nourishment is not so distant”. Neurochemistry International 89 (2015): 1-6.
23. Loffredo L., et al. “Antioxidant and antiplatelet activity by polyphenol-rich nutrients: focus on extravirgin oil and cocoa”. British Journal of Clinical Pharmacology 83 (2017): 96–102.
24. Borghi C and Cicero AFG. “Nutraceuticals with clinically detectable blood pressure lowering effect: a review of available randomized clinical trials and their meta-analyses”. British Journal of Clinical Pharmacology 83 (2017): 163–171.
25. Holst B and Williamson G. “Nutrients and phytochemicals: from bioavailability to bioefficacy beyond antioxidants”. Current Opinion in Biotechnology 19 (2008): 73-82.
26. Banach M., et al. “The role of nutraceuticals in statin intolerant patients”. Journal of the American College of Cardiology1 (2018): 96-118.
27. Barrios V., et al. “A nutraceutical approach (Armolipid Plus) to reduce total LDL cholesterol in individuals with mild to moderate dyslipidemia: review of the clinical evidence”. Atherosclerosis Supplements 24 (2017): 1-15.
28. Sneader W., et al. Drug discovery. A history, John Wiley and Sons Ltd., Chichester UK (2005): 88-150.
29. Manach C., et al. “The complex links between dietary phytochemicals and human health deciphered by metabolomics”. Molecular Nutrition and Food Research 53 (2009): 1303-1315.
30. Renner S., et al. “Bioactivity-guided mapping and navigation of chemical space”. Nature Chemical Biology8 (2009): 585-592.
31. Koch MA., et al. “Charting biologically relevant chemicals pace: a structural classifications of natural products (SCONP)”. Proceedings of the National Academy of Sciences48 (2005): 17272-17277.
32. Mora C., et al “How many species are there on earth and in the ocean?”. PLoS Biology8 (2011): e1001127.
33. Matoli L., et al. “A metabolite fingerprinting for the characterization of commercial botanical dietary supplements”. Metabolomics 7 (2011): 437–445.
34. Shoyama Y. “Quality control of herbal medicines and related areas”. InTech Rijeka CR (2011).
35. Csermely P., et al. “Structure and dynamics of molecular networks: a novel paradigm of drug discovery, a comprehensive review”. Pharmacology and Therapeutics 138 (2013): 333-408.
36. Pevsner J. Bioinformatics and functional genomics, 3rd Ed., Wiley Blackwell Chichester UK 2015.
37. Quideau S., et al. “Plant Polyphenols: Chemical Properties, Biological Activities, and Synthesis”. Angewandte Chemie International Edition3 (2011): 586-621.
38. Del Rio D., et al. “Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases”. Antioxidants and Redox Signaling 18 (2013): 1818–1892.
39. Shahidi F., Ambigaipalan P. “Phenolics and polyphenolics in foods, beverages and spices: antioxidant activity and health effects – a review”. Journal of Functional Foods 18 (2015): 820-897.
40. Grynkiewicz G. “Plant isoflavones, their impact on life sciences, medicine and industry”. Frontiers in Natural Products Chemistry 3 (2017): 283-356.
41. Panche AN., et al. “Flavonoids: an overview”. Journal of Nutritional Sciences 5 (2016): 1-15.
42. Wang T., et al. “Bioactive flavonoids in medicinal plants: structure, activity and biological fate”. Asian Journal of Pharmaceutical Sciences 13 (2018): 12-23.
43. Grynkiewicz G and Szeja W. “Synthetic glycosides and glycoconjugates of low molecular weight natural products”. Current pharmaceutical design12 (2016): 1592-1627.
44. Yang B., et al. “New insights on bioactivities and biosynthesis of flavonoid glycosides”. Trends in Food Science and Technology 79 (2018): 116-124.
45. Aguillon AR., et al. “Synthetic strategies toward SGLT2 inhibitors”. Organic Process Research and Development 22 (2018): 467-488.
46. Rodriguez-Mateos A., et al. “Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: an update”. Archives of Toxicology 88 (2014): 1803-1853.
47. Pan M-H., et al. “Anti-inflammatory activity of natural dietary flavonoids”. Food and Function 1 (2010): 15-31.
48. Hoensch HP and Oertel R. “The value of flavonoids for the human nutrition: short review and perspectives”. Clinical Nutrition Experimental 3 (2015): 8-14.
49. Yousefzadeh MJ., et al. “Fisetin is a senotherapeutic that extends health and lifespan”. EBioMedicine 36 (2018): 18-28.
50. Grynkiewicz G and Demchuk OM. “New perspectives for fisetin”. Frontiers in Chemistry 7 (2019): 697-706.
51. Boeing H., et al. “Critical review: vegetables and fruit in the prevention of chronic diseases”. European Journal of Nutrition 51 (2012): 637-663.
52. Williamson G., et al. “The bioavailability, transport, and bioactivity of dietary flavonoids: a review from a historical perspective”. Comprehensive Reviews in Food Science and Food Safety 17 (2018): 1054-1112.
53. Stephanopoulos G. “Synthetic biology and metabolic engineering”. ACS SyntheticBiology 1 (2012): 514-525.
54. Trantas EA., et al. “When plants produce not enough or at all: metabolic engineering of flavonoids in microbial hosts”. Frontiers in Plant Sciences7 (2015): 1-16.
55. Bagchi D and Nair S. Developing New Functional Food and Nutraceutical Products”. Elsevier Amsterdam (2017).

Citation

Citation: Grzegorz Grynkiewicz. “Phytochemicals Between Nutrition and Medicine".Acta Scientific Nutritional Health 4.1 (2020): 24-29.

Copyright

Copyright: © 2020 Grzegorz Grynkiewicz. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.